GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

Home
/
update
/
details

Strand Life Sciences Introduces Liquid Biopsy Test to Enhance Cancer Diagnosis

NextEdge Admin

16 Sep 2024

2 min 16 sec

Reliance Industries Limited,Liquid Biopsy,precision medicine

Strand Life Sciences, a subsidiary of Reliance Industries Limited, announced the launch of its Somatic Advantage 74 Liquid Biopsy (SA74 LB) Test, designed to detect circulating tumor DNA in cancer patients through a blood sample. This test analyzes 74 clinically relevant genes, offering key insights for personalized cancer treatment.

With over 24 years of experience and 50,000 genetic tests conducted, Strand Life Sciences has developed the SA74 LB Test to ensure high accuracy and sensitivity using Unique Molecular Identifiers (UMIs). The test’s deep coverage, with over 15,000x pre-UMI and 2,000x post-UMI analysis, enhances its precision in detecting genetic variants. Strand’s CAP and NABL-accredited labs ensure the highest quality standards, adhering to international best practices.

The SA74 LB Test provides actionable insights by identifying genomic alterations in genes associated with solid tumor therapies, in line with FDA and NCCN guidelines. Its minimally invasive approach, requiring only a peripheral blood sample, makes it a convenient option for patients, particularly when traditional biopsies are not feasible or when tissue samples are insufficient.

According to the company, the SA74 LB Test is a significant advancement in cancer diagnostics, helping clinicians make timely, informed decisions to optimize treatment plans and improve patient outcomes. "This test makes genetic testing more accessible and beneficial to patients, showcasing Strand Life Sciences' commitment to advancing precision medicine," said Dr. Ramesh Hariharan, CEO of Strand Life Sciences.